CD28 and neoplasm: These studies suggest that CD28-based CAR-T cells with PYAP mutations lacking LCK binding may optimize CAR-T functionality by reducing IL-2-mediated support for Treg cells within the tumor microenvironment, thereby enhancing therapeutic efficacy against solid tumors.